Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
about
Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypesNonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.
P2860
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immune Reconstitution in Sever ...... Results (The Advanz-3 Trial).
@en
type
label
Immune Reconstitution in Sever ...... Results (The Advanz-3 Trial).
@en
prefLabel
Immune Reconstitution in Sever ...... Results (The Advanz-3 Trial).
@en
P2093
P50
P1476
Immune Reconstitution in Sever ...... Results (The Advanz-3 Trial).
@en
P2093
Advanz-3 Study Group
Alberto C Guardo
Anna Cruceta
Christian Manzardo
Daniel Podzamczer
Elena Ferrer
Iñaki Pérez
Jose M Gatell
Jose M Miro
Montserrat Loncà
P304
P356
10.1097/QAI.0000000000000567
P407
P577
2015-06-01T00:00:00Z